Publication date: Jul 09, 2023
Palmoplantar pustulosis (PPP), a chronic and stubborn skin disease, is mainly confined to the palms or/and soles, making it possible for localized use of therapeutic antibodies. In this real-world prospective cohort study, 8 patients with PPP received palms/soles injections of ixekizumab (0. 8 mg in 0. 1 ml) every 2 to 8 weeks due to the COVID-19 pandemic. The treatment endpoint was a 75% improvement from baseline in Palmoplantar Psoriasis Area and Severity Index (PPPASI 75). At week 8, 75%, 50% and 12. 5% of 8 patients reached PPPASI 50, PPPASI 75 and PPPASI 90. At week 12, 100%, 67. 5% and 25% of 8 patients reached PPPASI 50, PPPASI 75 and PPPASI 90. This is the first study to evaluate the efficacy and safety of local injection of micro-dose ixekizumab for PPP in real clinical practice. A high proportion of patients rapidly achieved PPPASI 75, and maintained long-term efficacy with satisfactory safety.
| Concepts | Keywords |
|---|---|
| 8weeks | Anti-interleukin-17A antibody |
| Antibodies | Ixekizumab |
| Palmoplantar | Local injection |
| Pandemic | micro-dose |
| Palmoplantar pustular | |
| Psoriasis |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | injection |
| disease | VO | dose |
| disease | MESH | skin disease |
| drug | DRUGBANK | Ixekizumab |
| disease | MESH | COVID-19 pandemic |
| disease | MESH | Psoriasis |